Oncology Venture today publishes a supplement to the prospectus published April 5, 2019

    NEXT STORY
    BioDelivery Sciences Acquires U.S. Commercial Rights to Symproic®
    PREV STORY
    Basilea shareholders approve all proposals of the Board of Directors at the Annual General Meeting
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Ultragenyx Announces Withdrawal of Marketing Authorization Application for Aceneuramic Acid Prolonged Release (Ace-ER) in the European Union

    NOVATO, Calif., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical ...

    author_avatar
    NASDAQ Market News

    BeiGene Presents Clinical Results of Tislelizumab in Relapsed/Refractory Classical Hodgkin’s Lymphoma at the 60th American Society of Hematology Annual Meeting

    Company to Host Investor Meeting and Webcast Today, December 3, at 8 pm PSTBEIJING, ...

    author_avatar
    NASDAQ Market News

    GIAPREZA™ (angiotensin II) Significantly Improved Survival of Patients with High APACHE II Scores in ATHOS-3 Study

    SAN DIEGO, Feb. 25, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC) today ...

    author_avatar
    NASDAQ Market News